Home  > Technologieangebote

Circulating microRNAs for diagnosis of Takotsubo-Cardiomyopathy

Reference Number TO 15-00337

Challenge

Takotsubo cardiomyopathy (TTC) is a life-threatening disorder, characterized by clinical symptoms which are indistinguishable from acute myocardial infarction (MI). In the acute stage, 10% of the TTC patients develop malignant arrhythmia, cardiogenic shock, or ventricular wall rupture with a mortality rate up to 8%. Unfortunately, no established biomarkers are available for the early diagnosis of TTC and cardiac catheterization remains the standard diagnostic test. Thus, there is a strong need for sensitive and specific biomarkers to differentiate TTC from acute MI in its early stage.

Early diagnosis of TTC: miR-16 and  miR-26a
Early diagnosis of TTC: miR-16 and miR-26a

Technology

MicroRNAs (miRNAs/miRs) emerge as promising sensitive and specific biomarkers for immediate diagnosis of cardiovascular diseases. The recently developed technology discloses a subset of four circulating miRNAs, allowing the early diagnosis of TTC. A unique signature of miR-1, miR-16, miR-26a, and miR-133a differentiates TTC from patients with acute myocardial infarction and healthy subjects. Thus, for the first time a group of miRNAs is presented as a robust biomarker to assess TTC in its acute phase.

Commercial Opportunity

In-licensing or collaboration for further development is possible.

Developmental Status

In-vitro assays with blood samples of humans patients were conducted for validation of microRNAs (TTC n=36, STEMI n=27, Healthy n=28).

Patent Situation

European patent (EP 3030672 B1) granted and validated in DE, GB, FR and CH.

Further Reading

Jaguszewski M, Osipova J, Thum T, Templin C et al. 2013. A signature of circulating microRNAs differentiates takotsubo cardiomyopathy from acute myocardial infarction. Eur Heart J. 35:999-1006